OTIC News and Press, Otonomy Inc. From 07/28/21

Otonomy Inc. (NASDAQ:OTIC) traded today at a new 52-week low of $1.66. Approximately 335,000 shares have changed hands today, as compared to an average 30-day volume of 345,000 shares. Otonomy Inc. share prices have moved between a 52-week high of $6.98 and the current low of $1.66 and a...

SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter 2021 and provide a corporate update at...

Otonomy Inc. (NASDAQ:OTIC) traded at a new 52-week low today of $1.80. So far today approximately 335,000 shares have been exchanged, as compared to an average 30-day volume of 342,000 shares. Over the past year, Otonomy Inc. has traded in a range of $1.80 to $6.98 and is now at $1.83. ...

Shares of Otonomy Inc. (NASDAQ:OTIC) traded at a new 52-week low today of $1.88. Approximately 335,000 shares have changed hands today, as compared to an average 30-day volume of 321,000 shares. Otonomy Inc. share prices have moved between a 52-week high of $6.98 and the current low of $...

Otonomy Inc. (NASDAQ:OTIC) traded today at a new 52-week low of $1.97. So far today approximately 335,000 shares have been exchanged, as compared to an average 30-day volume of 301,000 shares. There is potential upside of 26.5% for shares of Otonomy Inc. based on a current price of $2.00...

Shares of Otonomy Inc. (NASDAQ:OTIC) traded today at $2.00, breaking its 52-week low. So far today approximately 335,000 shares have been exchanged, as compared to an average 30-day volume of 296,000 shares. Potential upside of 24.0% exists for Otonomy Inc., based on a current level of $...

Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...

Otonomy (OTIC) announces the initiation of an expansion study for the Phase 1/2 clinical trial of OTO-413 in patients with speech-in-noise hearing difficulty.Shares up more than 10% premarket.OTO-413 is a proprietary, sustained-exposure formulation of brain-derived neurotrophic...

OTO-413 demonstrated a higher proportion of responders than placebo based on multiple speech-in-noise hearing tests in dose escalation efficacy cohort Expansion study will support endpoint selection and powering for Phase 2 Top-line results expected in mid-20...

Otonomy (OTIC) announces preclinical proof-of-concept results for OTO-825 at the ASGCT Annual Meeting. OTO-825 is an AAV-mediated gene therapy developed in collaboration with Applied Genetic Technologies Corporation (AGTC).The results demonstrate that a single administration of OTO-825 rescue...